---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060756"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:48:10.387640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics Q1 2023 revenue $6.2M, net loss $26.7M; KORSUVA vial demand doubles

## Summary
- Total revenue $6.2M (up from $4.8M YoY); net loss $26.7M ($0.49/sh) vs $27.7M ($0.52/sh) in Q1 2022.
- KORSUVA injection net sales $5.7M; vial shipments to dialysis centers 45,720, more than doubling QoQ.
- Cash, equivalents and securities $123.4M at March 31, 2023, down from $156.7M; cash runway into 2H24.
- Oral difelikefalin: KIND 1 atopic dermatitis Part A readout on track for 4Q23; KICK CKD topline 2H24; KOURAGE NP Part A 2H24.
- Kapruvia launched in four European countries; Japan PMDA decision expected 2H23.

## SEC filing metadata
- accession: 0001104659-23-060756
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/0001104659-23-060756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/tm2315680d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060756
- JSON: https://secwatch.observer/filing/0001104659-23-060756.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060756.txt

## Key facts
- Earnings Releases
  Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $6.2 million, net income $26.7 million, EPS $(0.49) per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $6.2 million
  - Net income: $26.7 million
  - EPS: $(0.49) per basic and diluted share
  - Result: reported results
  source text: For the first quarter of 2023, net loss was $26.7 million, or $(0.49) per basic and diluted share, compared to net loss of $27.7 million, or ($0.52) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.2 million and $4.8 million for the three months ended March 31, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/0001104659-23-060756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.